Biomimetic transport and rational drug delivery

Ranney, David F.

doi:10.1016/s0006-2952(99)00316-0

Cited by 57 publications

(31 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…79) Protein, peptides, vaccines, and oligonucleotides represent an important class of biotech drugs for which polymeric nanoparticles offer an attractive possibility. 60,82,83) Polymeric nanoparticles offer engineered specificity allowing them to deliver a higher concentration of pharmaceutical agent to a desired location. But, particulate drug carriers are subject to rapid removal from the circulation by the macrophages of MPS, the main obstacle in targeting various non-phagocytic cells of the body.…”

Section: Solid Lipid Nanoparticles (Sln)mentioning

confidence: 99%

Nanocarriers: Promising Vehicle for Bioactive Drugs

Rawat

Singh

Saraf

2006

Biological & Pharmaceutical Bulletin

386

183

View full text Add to dashboard Cite

Development of new delivery systems that deliver the potential drug specifically to the target site in order to meet the therapeutic needs of the patients at the required time and level remains the key challenge in the field of pharmaceutical biotechnology. Developments in this context to achieve desired goal has led to the evolution of the multidisciplinary field nanobiotechnology which involves the combination of two most promising technologies of 21st century-biotechnology and nanotechnology. Nanobiotechnology encompasses a wide array of different techniques to improve the delivery of biotech drugs, and nanoparticles offer the most suitable form whose properties can be tailored by chemical methods. This review highlights the different types of nanoparticulate delivery systems employed for biotech drugs in the field of molecular medicine with a short overlook at its applications and the probable associated drawbacks.

show abstract

Section: Solid Lipid Nanoparticles (Sln)mentioning

confidence: 99%

Nanocarriers: Promising Vehicle for Bioactive Drugs

Rawat

Singh

Saraf

2006

Biological & Pharmaceutical Bulletin

386

183

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 97%

“…For instance, as has recently been pointed out in a commentary on transvascular drug delivery (Ranney, 2000), only about 0.01% of certain intravenously administered genomic and biopharmaceutical agents reaches the final deep-tissue cellular targets. As has been experimentally observed for in vivo conditions, this retarded delivery involves the impedance of drug carriers which exposed hydrophobic or specific binding moieties (Ranney, 2000), resulting in steep concentration gradients. The presence of these concentration distributions impacts pharmacological effectiveness and disease state associated with tumor angiogenesis, invasive and metastatic behavior, and possibly desmoplasia (Anderson & Chaplain, 1998;Liotta & StetlerStevenson, 1993;Weinberg & Hanahan, 1996).…”

Section: Discussionmentioning

confidence: 97%

“…Nonuniformities in the source and loss mechanism(s) induce spatial variations in the material concentration distribution(s) (Stein, 1986). Such behavior is evident in, for example, tumor angiogenic stimulation and/or repression, (blood vessel recruitment by tumors) chemotherapeutic drug delivery, etc., involving solidFyet phenotypically heterogeneousFtumors, wherein spatially varying concentration profiles can develop in the avascular regions due to spatially varying biochemical source and loss effects (Vaupel et al, 1989;Erlanson et al, 1991;Konerding et al, 1992;Baxter et al, 1992;Cowan et al, 1996;Hicks et al, 1997;Mason et al, 1999;Ranney, 2000).…”

Section: Introductionmentioning

confidence: 99%

“…The reaction and diffusion involving the activation of latent growth factors by the proteases can be modelled at the macroscopic level using coupled multicomponent reactive diffusion. Additionally, many pharmacokinetic applications involve multicomponent reactive diffusion as drugs diffuse and bind to up or down regulate biochemical processes (Ranney, 2000). New innovations in codelivery polymeric systems involving interacting multicomponent drug delivery require model development to quantify drug release through polymers (Narasimhan & Peppas, 1997).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A Fully Coupled Binary Biochemical Reactive-diffusion Model with Analytic Solution

Durkee

Antich

Lewis

et al. 2003

Journal of Theoretical Biology

View full text Add to dashboard Cite

Dual‐Targeting to Cancer Cells and M2 Macrophages via Biomimetic Delivery of Mannosylated Albumin Nanoparticles for Drug‐Resistant Cancer Therapy

Zhao

Yin

et al. 2017

Adv Funct Materials

137

View full text Add to dashboard Cite

Multidrug resistance (MDR) is an issue that is not only related to cancer cells but also associated with the tumor microenvironments. MDR involves the complicated cancer cellular events and the crosstalk between cancer cells and their surroundings. Ideally, an effective system against MDR cancer should take dual action on both cancer cells and tumor microenvironments. The authors find that both the drug‐resistant colon cancer cells and the protumor M2 macrophages highly express two nutrient transporters, i.e., secreted protein acidic and rich in cysteine (SPARC) and mannose receptors (MR). By targeting SPARC and MR, a system can act on both cancer cells and M2 macrophages. Herein the authors develop a mannosylated albumin nanoparticles with coencapsulation of different drugs, i.e., disulfiram/copper complex (DSF/Cu) and regorafenib (Rego). The results show that combination therapy of DSF/Cu and Rego efficiently inhibits the growth of drug‐resistant colon tumor, and the combination has not been reported yet for use in anticancer treatment. The system significantly improves the treatment outcomes in the animal model bearing drug‐resistant tumors. The therapeutic mechanisms involve enhanced apoptosis, upregulation of intracellular ROS, anti‐angiogenesis, and tumor‐associated macrophage “re‐education.” This strategy is characterized by dual targeting to and the simultaneous action on cancer cells and M2 macrophages, with biomimetic codelivery of a novel drug combination.

show abstract

Biomimetic transport and rational drug delivery

Cited by 57 publications

References 57 publications

Nanocarriers: Promising Vehicle for Bioactive Drugs

Nanocarriers: Promising Vehicle for Bioactive Drugs

A Fully Coupled Binary Biochemical Reactive-diffusion Model with Analytic Solution

Dual‐Targeting to Cancer Cells and M2 Macrophages via Biomimetic Delivery of Mannosylated Albumin Nanoparticles for Drug‐Resistant Cancer Therapy

Contact Info

Product

Resources

About